These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16234130)

  • 1. The relationship between take-away methadone policies and methadone diversion.
    Ritter A; Di Natale R
    Drug Alcohol Rev; 2005 Jul; 24(4):347-52. PubMed ID: 16234130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.
    Winstock AR; Lea T; Sheridan J
    Int J Drug Policy; 2008 Dec; 19(6):450-8. PubMed ID: 18359216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buprenorphine injection in Melbourne, Australia--an update.
    Aitken CK; Higgs PG; Hellard ME
    Drug Alcohol Rev; 2008 Mar; 27(2):197-9. PubMed ID: 18264882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An epidemiological investigation into an outbreak of rash illness among methadone maintenance clients in Australia.
    McAnulty JM; Jauncey ME; Monger CK; Hailstone ST; Alam NK; Mannes TF; Capon AG; Irvine K; Armstrong PK; Kaldor JM
    Drug Alcohol Rev; 2007 May; 26(3):321-31. PubMed ID: 17454022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harm reduction drug policies and practice: international developments and domestic initiatives. Overview of a symposium. March 22, 1995.
    Drucker E; Hantman JA
    Bull N Y Acad Med; 1995; 72(2):335-8. PubMed ID: 10101373
    [No Abstract]   [Full Text] [Related]  

  • 6. Trends in morphine prescriptions, illicit morphine use and associated harms among regular injecting drug users in Australia.
    Degenhardt L; Black E; Breen C; Bruno R; Kinner S; Roxburgh A; Fry C; Jenkinson R; Ward J; Fetherston J; Weekley J; Fischer J
    Drug Alcohol Rev; 2006 Sep; 25(5):403-12. PubMed ID: 16939934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methadone injecting in Australia: a tale of two cities.
    Lintzeris N; Lenné M; Ritter A
    Addiction; 1999 Aug; 94(8):1175-8. PubMed ID: 10615732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of problematic and injecting drug use for Drug Action Team areas in England.
    Frisher M; Heatlie H; Hickman M
    J Public Health (Oxf); 2006 Mar; 28(1):3-9. PubMed ID: 16436448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in reducing cannabis-related harm in Australia.
    Hall WD
    Drug Alcohol Rev; 2009 Mar; 28(2):110-6. PubMed ID: 19320694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supply control policy, harm reduction and context dependence.
    Weatherburn D
    Addiction; 2005 Jul; 100(7):927-8; discussion 930-2. PubMed ID: 15955006
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of FDA approval of a generic competitor to OxyContin (oxycodone HCl controlled-release) tablets on the abuse of oxycodone.
    Bailey JE; Barton PL; Lezotte D; Lowenstein SR; Dart RC
    Drug Alcohol Depend; 2006 Sep; 84(2):182-7. PubMed ID: 16510252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The contribution of research to the development of a national cannabis policy in Australia.
    Hall WD
    Addiction; 2008 May; 103(5):712-20. PubMed ID: 18412748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Social control and coercion in addiction treatment: towards evidence-based policy and practice.
    Wild TC
    Addiction; 2006 Jan; 101(1):40-9. PubMed ID: 16393190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users.
    Van Den Berg C; Smit C; Van Brussel G; Coutinho R; Prins M;
    Addiction; 2007 Sep; 102(9):1454-62. PubMed ID: 17697278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How do treatment repeaters use the drug treatment system? An analysis of injection drug users in Massachusetts.
    Lundgren LM; Sullivan L; Amodeo M
    J Subst Abuse Treat; 2006 Mar; 30(2):121-8. PubMed ID: 16490675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harm reduction: Australia as a case study.
    Wodak A
    Bull N Y Acad Med; 1995; 72(2):339-47. PubMed ID: 10101374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of methadone treatment on incarceration rates among injection drug users.
    Werb D; Kerr T; Marsh D; Li K; Montaner J; Wood E
    Eur Addict Res; 2008; 14(3):143-9. PubMed ID: 18552490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. School, parent, and student perspectives of school drug policies.
    Evans-Whipp TJ; Bond L; Toumbourou JW; Catalano RF
    J Sch Health; 2007 Mar; 77(3):138-46; quiz 153-4. PubMed ID: 17302856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence-based policy or policy-based evidence? The role of evidence in the development and implementation of the Illicit Drug Diversion Initiative.
    Hughes CE
    Drug Alcohol Rev; 2007 Jul; 26(4):363-8. PubMed ID: 17564871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.